Targeting BCMA in Multiple Myeloma.
Targeting BCMA in Multiple Myeloma.
复制标题
DOI：
10.1007/s11899-021-00639-z
复制
发表时间：
2021-10
影响因子：
2.9
通讯作者：
中科院分区：
文献类型：
--
作者：
尽管过去十年多发性骨髓瘤(MM)的治疗取得了长足的进步，但仍有相当数量的患者在现有的治疗方法上取得了进展。在这里，我们回顾了在MM的治疗中靶向BCMA的治疗方式，特别是抗体-药物结合物(ADC)、双特异性抗体构建体和嵌合抗原受体(CAR)修饰的T细胞疗法。我们将提供这些类别的疗法的概述，这些疗法已经公布或发表了临床数据，以及关于对这些新药的耐药性机制的数据。探索不同的BCMA靶向治疗多发性骨髓瘤的临床试验正在进行中，并显示出令人振奋的结果。在复发/难治性多发性骨髓瘤中，抗BCMA ADC和双特异性抗体构建物显示出令人印象深刻的疗效和可控的副作用。同时，过继细胞治疗已经在复发性和难治性骨髓瘤患者中诱导了戏剧性的持久反应。针对BCMA的治疗方法在多发性骨髓瘤的治疗中具有巨大的潜力，并将很快与当前的标准治疗相结合，以改善多发性骨髓瘤患者的预后。此外，正在评估克服抗BCMA疗法耐药机制的新方法。
Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a significant number of patients still progress on current available therapies. Here we review treatment modalities used to target BCMA in the treatment of MM, specifically antibody-drug conjugates (ADC), bispecific antibody constructs, and chimeric antigen receptor (CAR) modified T-cell therapies. We will provide an overview of therapies from these classes that have presented or published clinical data, as well as data on mechanisms of resistance to these novel agents. Clinical trials exploring different BCMA-targeting modalities to treat multiple myeloma are underway and demonstrate promising results. In relapsed/refractory multiple myeloma, anti-BCMA ADCs and bispecific antibody constructs are showing impressive efficacy with manageable side effect profiles. In parallel, adoptive cellular therapy have induced dramatic durable responses in multiply relapsed and refractory myeloma patients. Therapeutic approaches targeting BCMA hold significant potential in the management of multiple myeloma and will soon be incorporated in combination with current standard therapies to improve outcomes for patients with multiple myeloma. In addition, novel approaches are being evaluated to overcome resistance mechanisms to anti-BCMA therapies.
登录
查看更多内容
影响因子：
11.4
作者：
Gandhi, Ujjawal H.;Cornell, Robert F.;Costa, Luciano J.
通讯作者：
Costa, Luciano J.
影响因子：
2.7
作者：
Chen, Haiming;Li, Mingjie;Berenson, James R.
通讯作者：
Berenson, James R.
DOI：
10.1016/s0140-6736(16)31594-x
发表时间：
2017-02-04
期刊：
Lancet (London, England)
影响因子：
--
作者：
Durie BGM;Hoering A;Abidi MH;Rajkumar SV;Epstein J;Kahanic SP;Thakuri M;Reu F;Reynolds CM;Sexton R;Orlowski RZ;Barlogie B;Dispenzieri A
通讯作者：
Dispenzieri A
影响因子：
7.5
作者：
Cohen, Adam D.;Garfall, Alfred L.;Lesokhin, Alexander M.
通讯作者：
Lesokhin, Alexander M.
影响因子：
14.8
作者：
Labrijn, Aran F.;Meesters, Joyce I.;Parren, Paul W. H. I.
通讯作者：
Parren, Paul W. H. I.